Publications

5810 Results

The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity

Authors
L Minasian;E Dimond;M Davis;B Adhikari;R Fagerstrom;C Fabian;J Floyd;J Unger;P Douglas;K Mustian;EJ Chow;S Lipshultz;G Hundley;S Armenian;B Ky
Journal / Conference
JACC: Cardiooncology Sept 1(1):105-113
Year
2019
Research Committee(s)
Palliative Care
PMID
PMID32529192
PMC
PMC7288847
Study Number(s)
S1501

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI

Authors
C Tangen;J Schenk;C Till;P Goodman;W Barrington;M Lucia;I Thompson
Journal / Conference
Cancer Epidemiology Dec 63, 101619
Year
2019
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID31639607
PMC
PMC6938232
Study Number(s)
S0000

Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma [Brief Reports]

Authors
M Kamdar;H Li;R Chen;L Rimsza;M Leblanc;T Fenske;T Shea;P Barr;T Phillips;B Kahl;J Friedberg;SM Smith
Journal / Conference
Blood Advances Oct 22;3(20): 3132-3135
Year
2019
Research Committee(s)
Lymphoma
PMID
PMID31648328
PMC
PMC6849956
Study Number(s)
S1106

Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications

Authors
JM Unger;V Nghiem;D Hershman;R Vaidya;M Leblanc;CD Blanke
Journal / Conference
JAMA Open Network Sep 4;2(9):e1910593
Year
2019
Research Committee(s)
Cancer Care Delivery
PMID
PMID31483471
PMC
PMC6727679

A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events

Authors
SM Lee;J Miao;JM Unger;K Cheung;DL Hershman
Journal / Conference
Health and Quality of Life Outcomes Aug 22;17(1):146
Year
2019
Research Committee(s)
Genitourinary
PMID
PMID31438967
PMC
PMC6704545
Study Number(s)
S9916

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

Authors
T Synold;M Plets;C Tangen;E Heath;G Palapattu;P Mack;M Stein;M Meng;P Lara;N Vogelzang;IM Thompson;CR Ryan
Journal / Conference
Kidney Cancer Aug 7;3(2):111-118
Year
2019
Research Committee(s)
Genitourinary
PMID
PMID31763512
PMC
PMC6864417
Study Number(s)
S0931

The accuracy of clinical staging of stage I-III non-small cell lung cancer: An analysis based on individual participant data [on behalf of the NSCLC Meta-analysis Collaborative Group (K Kelly)]

Authors
N Navani;D Fisher;J Tierney;S Burdett;SWOG Collaborators:;PA Bunn;E Vallieres
Journal / Conference
Chest Mar;155(3):502-509
Year
2019
Research Committee(s)
Lung
PMID
PMID30391190
PMC
PMC6435782
Study Number(s)
S9900

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial

Authors
G Abou-Alfa;Q Shi;J Knox;A Kaubisch;D Niedzwiecki;J Posey;B Tan;P Kavan;R Goel;P Lammers;T Bekaii-Saab;VC Tam;L Rajdev;R Kelley;A El-Khoueiry;I El Dika;T Zemla;R Potaracke;J Balletti;L Schwartz;RM Goldberg;M Bertagnolli;J Meyerhardt;E O'Reilly;A Venook
Journal / Conference
JAMA Oncology Sep 5;5(11):1582-1588; Sep 5;. doi: 10.1001/jamaoncol.2019.2792. [Epub ahead of print]
Year
2019
Research Committee(s)
Gastrointestinal
PMID
PMID31486832
PMC
PMC6735405
Study Number(s)
CTSU/C80802

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB(Alliance)/SWOG 80405

Authors
B Guercio;S Zhang;F-S Ou;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;R Goldberg;K Sato;K Ng;E Van Blarigan;RJ Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt
Journal / Conference
Journal of Clinical Oncology Oct 10;37(29):2620-2631
Year
2019
Research Committee(s)
Gastrointestinal
PMID
PMID31408415
PMC
PMC6900834
Study Number(s)
CTSU/C80405

5a-Reductase Inhibitor Use in Patients With Prostate Cancer [Letter to the Editor/Comment & Response] re: Sarkar RR, Parsons JK, Bryant AK, et al.]

Authors
IM Thompson;CM Tangen;B Kramer
Journal / Conference
JAMA Internal Medicine Oct 1;179(10):1440
Year
2019
Research Committee(s)
Cancer Control
PMID
PMID31589258
Study Number(s)
SWOG-9217